Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4656 Development of a 3D patient-derived extracellular matrix hydrogel model of small intestinal neuroendocrine tumour and mesenteric fibrosis

Introduction: The pathogenesis of mesenteric fibrosis in small intestinal neuroendocrine tumours (SI-NETs) is poorly understood, limiting development of effective treatments and biomarkers. A major barrier to research is the lack of disease models.

Conference:

Presenting Author:

Authors: Hodgetts H, Martins M, Luong T, Hall A, Webster A,

Keywords: small intestine, neuroendocrine, 3D model, hydrogel, fibrosis,

#4455 Multicentric ENETS morphological and molecular appraisal of high-grade gastroenteropancreatic neuroendocrine neoplasms (HG-GEP-NEN): Distinguishing NET G3 from NEC

Introduction: HG-GEP-NEN are classified into neuroendocrine tumours grade 3 (NET G3) and neuroendocrine carcinomas (NEC). This distinction is crucial as it affects patient prognosis and treatments but can be challenging.

Conference:

Presenting Author: Tihy M

Authors: Tihy M, Solstad O, Oudijk L, Bräutigam K, Bani M,

Keywords: HG-GEP-NEN, neuroendocrine neoplasm, NEC, NET G3, Classification, Review, criteria, diagnosis, pathology,

#4399 Updated data from a single-arm, open-label, multicentre clinical study on the efficacy and safety of surufatinib combined with EP regimen and serplulimab in first-line treatment of NEC

Introduction: NEC is an aggressive neuroendocrine neoplasm with limited treatment options. Surufatinib (SUR), a kinase inhibitor targeting VEGFRs, FGFR-1, and CSF-1R, improves vascular normalisation and tumour microenvironment, synergising with chemo- and immunotherapy.

Conference:

Presenting Author: Lin Z

Authors: Zhang T, Lin Z, Zhao L, Ma H, Zhang D,

Keywords: NEC, surufatinib, EP, first-line,

#4041 Mesenteric fibrosis in small intestinal neuroendocrine tumors (SI-NETs): Pathogenesis and therapeutic targets

Introduction: Mesenteric fibrosis (MF) affects up to 50% of small intestine neuroendocrine tumor (SI-NET) patients, causing significant morbidity and mortality. MF pathophysiology is poorly understood, limiting treatment development and biomarker identification.

Conference:

Presenting Author:

Authors: Castanho Martins M, Hodgetts H, Lemos Dias M, Luong T, Hall A,

Keywords: fibrosis, small intestine, 3D model, cell crosstalk, microenvironment, cancer-associated fibroblast,

#3793 Decellularised pancreas explants as a novel 3D model for pancreatic neuroendocrine tumors (PNETs) biomarker discovery

Introduction: The lack of preclinical models of pancreatic neuroendocrine tumors (pNETs) challenges advancement in biomarker discovery. Culturing cancer cells in their native tissue enables the study of complex tumor cell-ECM interactions, products of which could be utilised as disease biomarkers.

Conference:

Presenting Author: Ney A

Authors: Ney A, Al-Akkad W, Sedlak E, Garcia-Sampedro A, Hall A,

Keywords: Disease model, Tumor microenvironment, Biomarker discovery, Pancreatic NET,